Howson Pharmaceuticals Paliquinone Slow Release Tablet Listing Application Update: In Approval Is Expected to Become the First Imitation

Recently, Howson Pharmaceuticals reported the listing of four new generic drugs paleitolone probation tablets, in China's State Drug Administration (NMPA) review and approval status updated to: in the approvalIf positive results are obtained after approval, the product will become the first approved generic version of palicodone to be approved and will be treated as a consistency evaluationJust a week ago, Howson Pharmaceuticals approved the new four-class version of Malayacid Afatini, China's first generic drugPaliquinolone is an active metabolite of lipesterone, which has strong D2 receptors and 5-HT2A receptor blocking effects, which relieve sirritated psychotic-positive symptoms while improving cognitive and emotional symptomsThe original producer of the Paliquinone re-release tablet was Jansen Pharmaceuticals, a subsidiary of Johnson and Johnson, inc., which was listed in the U.Sin 2006 under the commodity name INVEGAIn China, the original research product Paliquinone slow release tablets were approved for sale in 2008 under the commercial name of the product, Zida, for the treatment of adult schizophreniaIn 2017, the drug was again approved by NMPA for treatment of people with schizophrenia in adolescents (12-17 years old, weighing 29 kg)At present, China only pariquinone slow release tablets imported original research products on the market, has not yet been approved for generic drugsIn March 2019, Howson Pharmaceuticals submitted to NMPA its application for listing of Paliquinone, becoming the first company in China to submit an application for listing of the productIn December of the same year, similar products from Oei Pharmaceuticals, a stone pharmaceutical group, also submitted a listing application, it is worth mentioning that the application was included in the priority review in January this yearAt present, the application for listing of Paliquinone slow release tablets of is in the process of review and approvalThis time, Howson Pharmaceuticals Paliquinone slow release tablets in the NMPA acceptance status updated to: in the approval, the end of the approval is the certification stageIf all goes well, Howson Pharmaceuticals is expected to take the first generic drug from the Paliquinone slow release tabletAs the new 4 generics are declared for market, if approved, the product will be treated as a consistency evaluationIn recent years, paliquina-relieved tablets have become a first-line drug option for the first patients with depressionThe original research product sina has entered China's national basic drug catalog in 2018 and the national health insurance directory in 2019 According to IMS data, paliquinone slow release tablets had global sales of about $700 million in 2016.